This article was updated on 17 Sept 2026.
NICE has approved the use of a new immunotherapy for treating house dust mite-related allergic rhinitis.
This guidance was published in March 2025 and updated in Aug 2026. The update is that the marketing authorisation has been expanded to include 5 to 11 year olds (it was previously restricted to those age 12 and over).